A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

Inclusion Criteria Patients must be: Healthy HIV-seropositive adults (generalized lymphadenopathy, seborrheic dermatitis acceptable). Negative for HIV plasma culture. Available for 6 months follow-up (patients in Pilot study) or 10 months follow-up (patients in Parts A and B). Prior Medication: Required: Part B: Zidovudine (AZT), tolerating a dose of 500 - 600 mg/day for at least 4 months prior to entry. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Evidence of psychological disorder during the past year that would impair adherence to the protocol. Evidence of an AIDS defining opportunistic infection. Prior Medication: Excluded: Any potential immunomodulating agents (e.g., isoprinosine, imuthiol, lithium) within 90 days of screening. Immunosuppressive medications during the past 3 months. Part A: Use of zidovudine (AZT) for more than 30 days in the preceding 6 months, or any AZT within the last 30 days. Parts A and B: Any non-AZT antiretroviral drug. Any other investigational agent within the past 30 days. Immunoglobulins within the past 60 days. Patients may not have the following prior conditions: Evidence of psychological disorder during the past year that would impair adherence to the protocol. History of an AIDS-defining opportunistic infection. Use of illicit drugs or significant amounts of alcohol that, in the opinion of the principal investigator, would interfere with compliance with the study.